Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

Citigroup Keeps Stryker Buy Rating, Boosts Target Despite Leadership Shift

Citigroup keeps a buy rating on Stryker, citing robust leadership plans and a diversified product pipeline that could drive earnings growth and lower device costs.

Dr. Sarah Winters

25/12/2025, 03:13

3 minutes to read

Swiss Shares Snapshot: Straumann Shares Dip While SMI Nears Record High

Swiss shares snapshot: Straumann Holding dips while the SMI hits a near‑record high – a market‑driven move, no company news, and steady dental‑implant prospects.

Dr. Sarah Winters

24/12/2025, 18:18

2 minutes to read

UnitedHealth’s 23‑Point Reform Plan & Mental‑Health Expansion: What Investors, Patients and Providers Must Know

UnitedHealth Group’s 23‑point corrective plan tackles audit‑identified risks while expanding adolescent mental‑health coverage, aiming to restore investor confidence and improve patient care amid regulatory pressure.

Dr. Sarah Winters

24/12/2025, 13:30

4 minutes to read

HCA Healthcare: Strong ASC Growth, Quality Leadership, and Earnings Outlook

HCA Healthcare’s solid finances, ASC growth plans, and new quality leadership at HCA Florida JFK Hospital signal strong investor appeal and patient‑centered gains ahead of the next earnings release.

Dr. Sarah Winters

24/12/2025, 01:42

3 minutes to read

UnitedHealth’s 23‑Point Plan: Strengthening Governance, Cutting Rebate Gaps & Expanding Free Adolescent Depression Care

UnitedHealth’s 23‑point action plan tackles audit gaps, pricing and subsidy changes while adding zero‑copay adolescent depression coverage, boosting access and compliance.

Dr. Sarah Winters

23/12/2025, 11:35

4 minutes to read

Regeneron Prepares JPMHC Talk: Strong Pipeline, Growing Investor Interest

Regeneron’s JPMHC appearance highlights new COVID‑19, cancer and gene‑editing breakthroughs, showing strong efficacy, safety and growth prospects.

Dr. Sarah Winters

23/12/2025, 05:18

3 minutes to read

Merck & Co. Sustains Strong Market Position with Safe, Efficacious Therapies

Merck & Co. remains a stable leader in healthcare, offering safe, effective biologics and vaccines with strong regulatory support—ideal for investors and clinicians seeking reliable value.

Dr. Sarah Winters

22/12/2025, 20:33

2 minutes to read

How Bayer AG’s Stock Performance and Diversified Portfolio Shape Investor Outlook in 2024

Explore Bayer AG’s latest stock move, market cap and five‑segment portfolio, and how earnings volatility and upcoming regulatory milestones shape investor outlook.

Dr. Sarah Winters

22/12/2025, 08:21

3 minutes to read

Zoetis Stock Surges on Strong Vaccine Portfolio and Global Health Gains

Zoetis Inc. stays resilient amid livestock‑sector headwinds with a proven vaccine and therapeutic portfolio, low resistance rates, and a growing digital health strategy that safeguards animal health worldwide.

Dr. Sarah Winters

22/12/2025, 05:29

4 minutes to read

Insmed’s Phase 2b Trial Failure Spurs Analyst Cuts, But Buy Ratings & Call‑Option Surge Signal Hope

Insmed’s Phase 2b BiRCh trial setback drops stock price, yet Gold‑Man and Truist keep a buy rating and call‑option volume rises—signaling cautious optimism for future upside.

Dr. Sarah Winters

21/12/2025, 13:22

3 minutes to read

Newer articles